Vertex Pharmaceuticals (NASDAQ: VRTX) has given more than one investor a headache over the past year. Investors worry that Vertex is struggling to expand beyond its core portfolio of cystic fibrosis (CF) treatments. Considering the time Vertex shares have spent in the doldrums, you may be getting a little impatient.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting